Related Experiment Video

Updated: Jun 5, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

Wendy De Roock1, Veerle De Vriendt, Nicola Normanno

  • 1Centre for Human Genetics, Catholic University of Leuven, Leuven, Belgium.

The Lancet. Oncology
|December 18, 2010
PubMed

Insights

Mutant KRAS predicts resistance to EGFR inhibitors in colorectal cancer, revealing gaps in understanding key signaling pathways. Targeting other oncogenic alterations may improve treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Mutant KRAS is a key predictor of resistance to epidermal growth-factor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer.
  • This discovery underscores limited knowledge of critical signaling pathways in colorectal tumors.
  • Targeting oncogenic alterations like phospho-MAP2K (MEK), phospho-AKT, and mutant B-RAF shows promise in combination with EGFR inhibitors.

Purpose of the Study:

  • To review the role of non-KRAS gene mutations in anti-EGFR therapy efficacy.
  • To discuss strategies for targeting these oncogenic alterations.
  • To explore combination therapies with receptor tyrosine-kinase inhibition.

Main Methods:

  • Literature review of studies on KRAS mutations and EGFR inhibitor resistance.
  • Analysis of signaling pathways in colorectal tumors.
  • Discussion of potential therapeutic targets and combination strategies.

Main Results:

  • Understanding of precise roles and oncogenic dependence on targets like MEK, AKT, and B-RAF in colorectal tumors is lagging.
  • Patient selection and treatment effect prediction remain challenging due to incomplete knowledge.
  • Non-KRAS mutations significantly influence the efficacy of anti-EGFR therapy.

Conclusions:

  • Further research is needed to elucidate the roles of various oncogenic alterations in colorectal cancer.
  • Targeting specific pathways beyond KRAS, alone or in combination with EGFR inhibitors, may offer improved treatment outcomes.
  • Addressing knowledge gaps is crucial for optimizing patient selection and predicting treatment response.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...